查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1611039

抗血管內皮生長因子治療市場規模、佔有率、趨勢分析報告：按產品、疾病、地區、細分市場預測，2025-2030

Anti-vascular Endothelial Growth Factor Therapeutics Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

抗血管內皮生長因子治療市場成長與趨勢

根據Grand View Research, Inc.最新報告，預計到2030年，全球抗血管內皮生長因子治療市場規模將達到129億美元，預測期內複合年成長率為-2.35%。增加抗 VEGF 治療研究和開發資金以加速開發新藥預計將加速市場成長。此外，新的創新產品的採用，加上更容易患眼疾的老年人數量的增加，預計將在預測期內推動市場成長。

根據聯合國經濟和社會事務部的資料，2019年全球約有7.03億老年人（60歲以上）。 65歲以上人口比例為6%，2019年增加至9%。從各國人口老化情況來看，2017年非洲約6,870萬人，亞洲約5.492億人，歐洲約1.83億人，北美約7,840萬人，拉丁美洲和拉丁美洲約7,840萬人。萬人。因此，老年人口的增加預計將推動市場。

開發中地區缺乏報銷政策為尋找新的、具成本效益的分子創造了機會。此外，隨著眼科醫生轉向更有效的新藥物，公司被迫投資於研發以維持其產業地位。研究人員對現有藥物的生物相似藥的興趣是抗 VEGF 治療管道的一個主要趨勢。

此外，公司正在開發各種製劑和藥物傳輸系統，有可能增加這些治療的採用。例如，羅氏公司（F. Hoffmann-La Roche Ltd.）開發了一種端口輸送系統－RG6321（雷珠單抗），目前正在進行III期臨床試驗。這是一種可再填充的眼部植入，可在幾個月內連續提供客製化的雷珠單抗配方。

失去專利保護可能會對市場成長產生負面影響，主要企業考慮新的收益來源。然而，生物相似藥生產商的新興市場正在形成。競爭的加劇預計將阻礙市場成長。然而，由於具有競爭優勢的新產品的推出，預計預測期內限制的影響較小。

抗血管內皮生長因子療法市場報告亮點

  • 老齡化黃斑部病變(AMD) 在 2024 年佔據最大的收益佔有率，預計在預測期內將保持其主導地位。
  • 2024 年，Eylea 擁有最大的產品市場佔有率，達到 61.9%。 Eylea（aflibercept）是再生元製藥與拜耳合作開發的抗 VEGF 治療藥物，是濕性老齡化黃斑部病變（AMD）、糖尿病黃斑部水腫（DME）和視網膜靜脈曲張等視網膜疾病的一線治療藥物他已經成為一個人。
  • 北美抗血管內皮生長因子治療市場主導全球產業，2024年佔銷售佔有率的65.71%。這是由於與老齡化的黃斑部病變（AMD）、糖尿病視網膜病變、視網膜靜脈阻塞和黃斑部水腫等眼部相關疾病的盛行率不斷增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章抗血管內皮生長因子治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 抗血管內皮生長因子治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章抗血管內皮生長因子治療市場：依產品估計與趨勢分析

  • 細分儀表板
  • 抗血管內皮生長因子治療市場：產品波動分析
  • 抗血管內皮生長因子治療市場：依產品分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 艾雷亞
  • Lucentis
  • 貝奧夫
  • 瓦維斯莫
  • 其他

第5章抗血管內皮生長因子治療市場：依疾病分類的估計與趨勢分析

  • 細分儀表板
  • 抗血管內皮生長因子治療市場：疾病波動分析
  • 抗血管內皮生長因子治療市場：依疾病分類的前景
  • 2018-2030年市場規模、預測及趨勢分析
  • 黃斑部水腫
  • 糖尿病視網膜病變
  • 視網膜靜脈阻塞
  • 老齡化黃斑部病變
  • 近視脈絡膜新生血管

第6章抗血管內皮生長因子治療市場：區域估計與趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 公司分類
  • 主要市場參與企業的最新趨勢和影響分析
  • 2024 年企業市場佔有率分析
  • 公司簡介
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Pfizer, Inc.
    • Coherus BioSciences, Inc.
    • Amgen, Inc.
    • Bausch Health Companies, Inc.
    • Viatris, Inc.
Product Code: GVR-4-68038-346-1

Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth & Trends:

The global anti-vascular endothelial growth factor therapeutics market size is expected to reach USD 12.90 billion by 2030, registering a CAGR of -2.35% over the forecast period, according to a new report by Grand View Research, Inc. Increased funding for R&D of anti-VEGF therapeutics to boost the development of new drugs is expected to accelerate market growth. Moreover, the introduction of novel innovative products coupled with the increasing geriatric population that is susceptible to develop ophthalmic diseases is expected to propel the market growth over the forecast period.

According to the United Nations Department of Economic and Social Affairs data, the global elderly population (aged 60 years and above) was around 703 million in 2019. The share of the population aged 65 years and above was 6%, which increased to 9% in 2019. The aging population, based on countries, was around 68.7 million in Africa, 549.2 million in Asia, 183 million in Europe, 78.4 million in North America, and more than 76 million in Latin America & other regions in 2017. Hence, the increasing geriatric population is anticipated to drive the market.

The lack of reimbursement policies in developing regions is creating an opportunity for cost-effective novel molecules. In addition, ophthalmologists switching to more effective newly launched drugs has compelled companies to invest in R&D to maintain their industry position. The interest of investigators on biosimilar of existing drugs is a major trend in the pipeline of anti-VEGF therapeutics.

Moreover, companies are developing various formulations and drug delivery systems that may increase the adoption of these therapies. For instance, F. Hoffmann La Roche Ltd. is developing the port delivery system-RG6321 (Ranibizumab)-which is currently undergoing a phase III clinical trial. It is an eye implant that is refillable and continuously delivers a customized formulation of ranibizumab over a period of months.

Loss of patent protection is likely to have a negative impact on the market growth and has led big pharma companies to consider new revenue streams. However, this is creating an emerging market for biosimilar drug producers in the space. This rising competition is anticipated to impede market growth. However, the launch of novel products with a competitive advantage is anticipated to lower the impact of the restraint during the forecast period.

Anti-vascular Endothelial Growth Factor Therapeutics Market Report Highlights:

  • In 2024, Age-related Macular Degeneration (AMD) accounted for the largest revenue share and is anticipated to maintain its dominance over the forecast period
  • Eylea dominated the product segment with the largest market share of 61.9% in 2024. Eylea (aflibercept), developed by Regeneron Pharmaceuticals in collaboration with Bayer, has been a foremost anti-VEGF therapy for treating retinal diseases such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO
  • North America anti-vascular endothelial growth factor therapeutics market dominated the global industry and accounted for 65.71% of revenue share in 2024, which can be attributed to the increasing prevalence of eye-related conditions such as age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, and macular edema

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Disease
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Disease outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of target diseases
      • 3.2.1.2. Advancements in drug delivery and development
      • 3.2.1.3. Rising awareness about early diagnosis and treatment of ocular disorders
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of anti-VEGF therapeutics
      • 3.2.2.2. Potential side effects and safety concerns
  • 3.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Product Movement Analysis
  • 4.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Product Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Eylea
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Lucentis
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.7. Beovu
    • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.8. Vabysmo
    • 4.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Disease Movement Analysis
  • 5.3. Anti-Vascular Endothelial Growth Factor Therapeutics Market by Disease Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Macular Edema
    • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Diabetic Retinopathy
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Retinal Vein Occlusion
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.8. Age-related Macular Degeneration
    • 5.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.9. Myopic Choroidal Neovascularization
    • 5.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Anti-Vascular Endothelial Growth Factor Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Company overview
    • 7.4.1. Regeneron Pharmaceuticals, Inc.
      • 7.4.1.1. Company Overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bayer AG
      • 7.4.2.1. Company Overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Novartis AG
      • 7.4.3.1. Company Overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. F. Hoffmann-La Roche Ltd.
      • 7.4.4.1. Company Overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Biogen
      • 7.4.5.1. Company Overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Pfizer, Inc.
      • 7.4.6.1. Company Overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Coherus BioSciences, Inc.
      • 7.4.7.1. Company Overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amgen, Inc.
      • 7.4.8.1. Company Overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Bausch Health Companies, Inc.
      • 7.4.9.1. Company Overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Viatris, Inc.
      • 7.4.10.1. Company Overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 4 Global anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 5 North America anti-vascular endothelial growth factor therapeutics, by region, 2018 - 2030 (USD Billion)
  • Table 6 North America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 7 North America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 8 U.S. anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 9 U.S. anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 10 Canada anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 11 Canada anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 12 Mexico anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 13 Mexico anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 14 Europe anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 15 Europe anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 16 Europe anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 17 UK anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 18 UK anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 19 Germany anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 20 Germany anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 21 France anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 22 France anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 23 Italy anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 24 Italy anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 25 Spain anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 26 Spain anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 27 Denmark anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 28 Denmark anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 29 Norway anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 30 Norway anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 31 Sweden anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 32 Sweden anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 33 Asia Pacific anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 34 Asia Pacific anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 35 Asia Pacific anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 36 Japan anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 37 Japan anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 38 China anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 39 China anti-vascular endothelial growth factor therapeutics, by disease 2018 - 2030 (USD Billion)
  • Table 40 India anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 41 India anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 42 Australia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 43 Australia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 44 South Korea anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 45 South Korea anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 46 Thailand anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 47 Thailand anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 48 Latin America anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 49 Latin America anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 50 Latin America anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 51 Brazil anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 52 Brazil anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 53 Argentina anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 54 Argentina anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 55 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by country, 2018 - 2030 (USD Billion)
  • Table 56 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 57 Middle East & Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 58 South Africa anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 59 South Africa anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 60 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 61 Saudi Arabia anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 62 UAE anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 63 UAE anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait anti-vascular endothelial growth factor therapeutics, by product, 2018 - 2030 (USD Billion)
  • Table 65 Kuwait anti-vascular endothelial growth factor therapeutics, by disease, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Anti-vascular endothelial growth factor therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and disease segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Parent market value, 2024 (USD Billion)
  • Fig. 12 Market dynamics
  • Fig. 13 Prevalence of diabetic retinopathy in the U.S. in 2021
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Anti-vascular endothelial growth factor therapeutics market: Product outlook and key takeaways
  • Fig. 17 Anti-vascular endothelial growth factor therapeutics market: Product movement analysis
  • Fig. 18 Eylea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lucentis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Beovu market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Vabysmo market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Anti-vascular endothelial growth factor therapeutics market: Disease outlook and key takeaways
  • Fig. 24 Anti-vascular endothelial growth factor therapeutics market: Disease movement analysis
  • Fig. 25 Macular edema market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Diabetic retinopathy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Retinal vein occlusion market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Age-related macular degeneration market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Myopic choroidal neovascularization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Anti-vascular endothelial growth factor therapeutics market revenue, by region, 2024 & 2030 USD Million
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 U.S. anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Prevalence of Diabetic Retinopathy (DR) in 2021, in U.S., in Million
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Mexico anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Europe anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 Germany anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 France anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Spain anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Italy anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Denmark anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Sweden anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Norway anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Japan anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Key country dynamics
  • Fig. 63 China anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 India anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Key country dynamics
  • Fig. 67 Australia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Key country dynamics
  • Fig. 69 Thailand anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 South Korea anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Brazil anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Argentina anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Rest of Asia Pacific anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Key country dynamics
  • Fig. 81 South Africa anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Key country dynamics
  • Fig. 83 Saudi Arabia anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 UAE anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Key country dynamic
  • Fig. 87 Kuwait anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Rest of MEA anti-vascular endothelial growth factor therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Company/competition categorization
  • Fig. 90 Company market share analysis, 2024
  • Fig. 91 Strategy mapping